A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Patient charts will be reviewed to evaluate the incidence of intraocular pressure spikes while on Loteprednol etabonate ophthalmic suspension 0.5%, Loteprednol etabonate (0.5%) and tobramycin (0.3%)

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Loteprednol Etabonate; Tobramycin

Criteria

Inclusion Criteria:

• Any patient who experienced an IOP spike while using Lotemax or Zylet will be included

Exclusion Criteria:

• N/A